Back to Search
Start Over
Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
- Source :
-
Nature reviews. Drug discovery [Nat Rev Drug Discov] 2016 Sep; Vol. 15 (9), pp. 589-590. Date of Electronic Publication: 2016 Jul 29. - Publication Year :
- 2016
-
Abstract
- A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
- Subjects :
- Anti-Bacterial Agents therapeutic use
Biomedical Research economics
Biomedical Research organization & administration
Clinical Trials as Topic
Humans
Anti-Bacterial Agents pharmacology
Bacterial Infections drug therapy
Bacterial Infections microbiology
Drug Resistance, Bacterial
Public-Private Sector Partnerships
Subjects
Details
- Language :
- English
- ISSN :
- 1474-1784
- Volume :
- 15
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Nature reviews. Drug discovery
- Publication Type :
- Academic Journal
- Accession number :
- 27469032
- Full Text :
- https://doi.org/10.1038/nrd.2016.155